Wolf Haldenstein Announces Investigation of Aegerion Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”)(NASDAQ:AEGR) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding its compliance with certain provisions of the Food Drug and Cosmetic Act, due to the Company’s off-label marketing of its flagship hypercholesterolemia drug, Juxtapid.